Cells treated with CHX showed accumulation of the alternatively spliced ABI2 product that was found to be increased in MS and EAE samples (Fig. 4h), confirming that the alternatively spliced product was a target for NMD. The gene discussed is ABI2; the disease is myeloid sarcoma.